Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00774267 · ClinicalTrials.gov registry record
Study Evaluating Changes In Mammographic Breast Density
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 507
- Enrollment target
NCT00774267 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 507 participants.
The verdict
NCT00774267 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 507 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mammographic breast density between baseline and month 24 for each group.
Interventions
- DRUG Placebo
- DRUG BZA 20 mg/CE 0.45 mg
- DRUG BZA 20 mg/CE 0.625 mg
- DRUG Raloxifene 60 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00774267
The ClinicalTrials.gov registry entry for NCT00774267 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00774267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00774267 about?
NCT00774267 is a clinical study titled "Study Evaluating Changes In Mammographic Breast Density". The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mam...
What is the current status of trial NCT00774267?
This trial is currently completed. The enrollment target is 507 participants. The study started on 2009-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00774267?
The interventions under investigation include: Placebo (DRUG), BZA 20 mg/CE 0.45 mg (DRUG), BZA 20 mg/CE 0.625 mg (DRUG), Raloxifene 60 mg (DRUG).
Who is sponsoring clinical trial NCT00774267?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.